Willow Biosciences Inc. (3D7.F)
| Previous close | 0.0565 |
| Open | 0.0530 |
| Bid | 0.0490 x N/A |
| Ask | 0.0730 x N/A |
| Day's range | 0.0530 - 0.0530 |
| 52-week range | 0.0395 - 0.0950 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 7.303M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0700 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.00 |
PR NewswireWILLOW BIOSCIENCES REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, today released its financial and operating results for the three months ended March 31, 2024, reporting significantly reduced costs and further progress in its commercial expansion.
Simply Wall St.Willow Biosciences Full Year 2023 Earnings: CA$0.10 loss per share (vs CA$0.12 loss in FY 2022)
Willow Biosciences ( TSE:WLLW ) Full Year 2023 Results Key Financial Results Revenue: CA$1.17m (up 43% from FY 2022...
PR NewswireWILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 FINANCIALS AND OPERATIONS AND FILING OF ITS 2023 AIF
Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable ingredients is pleased to announce its financial and operating results for the three months and year ended December 31, 2023, and filing of its Annual Information Form ("AIF"). Selected financial and operational information is outlined below and should be read with Willow's audited consolidated fin
